Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.
Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.
Cenibra is our sales and distribution partner for Imperacer® Services, Assay Development Kits and Imperacer® Workstations in Europe.
KPI Therapeutics is developing potentially game changing autoimmune therapies. Their platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Their lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as atopic dermatitis, myositis, and lupus, KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments.
Kineta® is an internationally-recognized biotechnology company focused on developing high need therapeutics in three large disease areas: autoimmune disease, viral disease and chronic pain.
German Sports University Cologne and Chimera Biotec support eachother's research on gene-doping and molecular pathways to identify doping. This research field is also supported by the World-Anti-Doping-Agency.